Drug Interactions between hyaluronidase and Scandonest L

GENERALLY AVOID: Hyaluronidase may enhance the absorption and dispersion of dopamine and/or other injectable alpha agonist drugs, resulting in cardiovascular effects such as increased blood pressure, increased vascular resistance and other alpha adrenergic-mediated adverse effects. Hyaluronidase is a dispersion agent, that can increase the permeability of connective tissue through the hydrolysis of hyaluronic acid. There are no clinical data available for this interaction.

MANAGEMENT: The manufacturer of hyaluronidase recommends avoiding the use of hyaluronidase to enhance the absorption and dispersion of dopamine and/or alpha agonist drugs. Some authorities consider this particular use of hyaluronidase as contraindicated. However, hyaluronidase used for other indications, may be administered to patients receiving dopamine and/or alpha agonist drugs. Consultation with product labeling and local or institutional guidelines may be appropriate for further recommendations.

When hyaluronidase is added to a local anesthetic, the local anesthetic solution undergoes increased absorption, resulting in a shorter duration of action and possible increased frequency of systemic reactions. The clinical significance is unknown. It may be advisable to monitor the patient for altered anesthetic efficacy and side effects.